FDA Announces Nationwide Recall of Levothyroxine Sodium Tablets
The U.S. Food and Drug Administration (FDA) has announced a nationwide recall of Levothyroxine Sodium Tablets due to a lack of full effectiveness.
Tampa St. Petersburg, FL, July 28, 2026 —
The U.S. Food and Drug Administration (FDA) has initiated a nationwide recall of Levothyroxine Sodium Tablets. The agency cited a lack of full effectiveness as the reason for the recall.
Levothyroxine Sodium Tablets are used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. The medication is crucial for regulating metabolism, energy levels, and other vital bodily functions.
The FDA’s announcement did not specify the exact number of affected batches or the specific manufacturers involved in the recall. The U.S. Food and Drug Administration has not provided details regarding the timeline for the recall’s implementation or the specific pharmacies and distributors that received the affected product. Further information regarding the scope of the recall is expected to be released by the agency.
Patients who are currently taking Levothyroxine Sodium Tablets are advised to consult with their healthcare provider. It is important for individuals to discuss their current medication and explore alternative treatment options if necessary. The FDA emphasized that patients should not discontinue their medication without consulting a medical professional.
The U.S. Food and Drug Administration is continuing its investigation into the product’s effectiveness and will provide updates as more information becomes available. The recall is a precautionary measure to ensure patient safety and the efficacy of prescribed treatments.
Story summarized from the original created by Zach Caplan on www.wfla.com, see more information here.
